Nav: Home

FDA approves drugs more quickly than peer agency in Europe

April 05, 2017

New Haven, Conn.-- The U.S. Food and Drug Administration (FDA) reviews and approves new medicines in a shorter timeframe than its peer agency in Europe, the European Medicines Agency (EMA), says a Yale researcher. This finding, which comes at a time when the FDA is under renewed pressure to streamline and speed up its approval process, provides data to inform ongoing policy discussions.

The report, co-authored with researchers at Brigham and Women's Hospital and New York University School of Medicine, was published April 5 by the New England Journal of Medicine.

The FDA has faced pressure from the public, politicians, and industry to accelerate review and approval of new medicines. The FDA's review process is currently being considered and reexamined as part of negotiations to reauthorize the law that directs funds to the agency - the Prescription Drug User Fee Act (PDUFA) -- due for reauthorization by October 2017.

To inform this debate, associate professor of medicine and public health Joseph Ross, M.D., and co-authors compared review times for new drugs approved by the FDA and the EMA between 2011 and 2015. They classified drugs according to therapeutic areas and "orphan" drugs, which are for rare diseases.

The researchers found that the FDA approved more new drugs than EMA -- 170 versus 144 -- in the study period. The median review time for FDA-approved drugs was quicker, 306 days compared to 383 days for EMA-approved drugs. Therapeutic medicines, particularly for cancer and blood diseases, were approved more quickly by the FDA than the EMA.

"The report provides data that demonstrates the FDA is moving faster than the European peer agency," said Ross.

The current analysis is an update to a prior paper led by Ross that found the FDA approved new medicines more quickly than the EMA and the drug approval agency in Canada. "The gap we had identified, where the FDA was 2-3 months faster, now it's about 3-4 months faster," he noted.

The data confirm that despite perceptions, the FDA completes regulatory reviews more quickly than similar agencies. "This is more information that should inform upcoming debates," Ross said. "The FDA is already making decisions quickly and increasing its regulatory speed shouldn't be our number-one priority."
-end-
Other authors are Nicholas Downing and Audrey Zhang.

There was no funding for this project. Ross receives research funding through Yale University from Medtronic, Inc. and the FDA to study issues in post-market surveillance, and from the FDA to establish the Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation.

Citation: New England Journal of Medicine

Yale University

Related Drugs Articles:

People are more likely to try drugs for the first time during the summer
American teenagers and adults are more likely to try illegal or recreational drugs for the first time in the summer, a new study shows.
A homing beacon for chemotherapy drugs
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy.
Drugs used to enhance sexual experiences, especially in UK
Combining drugs with sex is common regardless of gender or sexual orientation, reveals new research by UCL and the Global Drug Survey into global trends of substance-linked sex.
Promising new drugs for old pathogen Mtb
UConn researchers are targeting a metabolic pathway, the dihydrofolate reductase pathway, crucial for amino acid synthesis to treat TB infections.
Can psychedelic drugs heal?
Many people think of psychedelics as relics from the hippie generation or something taken by ravers and music festival-goers, but they may one day be used to treat disorders ranging from social anxiety to depression, according to research presented at the annual convention of the American Psychological Association.
More Drugs News and Drugs Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...